Shue YK - Search Results

1

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group. Louie TJ, et al. Among authors: shue yk. N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812. N Engl J Med. 2011. PMID: 21288078 Free article. Clinical Trial.

2

Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.

Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL. Mullane KM, et al. Among authors: shue yk. Clin Infect Dis. 2011 Sep;53(5):440-7. doi: 10.1093/cid/cir404. Clin Infect Dis. 2011. PMID: 21844027 Free PMC article.

3

Effect of age on treatment outcomes in Clostridium difficile infection.

Louie TJ, Miller MA, Crook DW, Lentnek A, Bernard L, High KP, Shue YK, Gorbach SL. Louie TJ, et al. Among authors: shue yk. J Am Geriatr Soc. 2013 Feb;61(2):222-30. doi: 10.1111/jgs.12090. Epub 2013 Feb 4. J Am Geriatr Soc. 2013. PMID: 23379974 Clinical Trial.

4

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, Okumu F, Preston RA. Shue YK, et al. Antimicrob Agents Chemother. 2008 Apr;52(4):1391-5. doi: 10.1128/AAC.01045-07. Epub 2008 Feb 11. Antimicrob Agents Chemother. 2008. PMID: 18268081 Free PMC article. Clinical Trial.

5

Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.

Liang CH, Romero A, Rabuka D, Sgarbi PW, Marby KA, Duffield J, Yao S, Cheng ML, Ichikawa Y, Sears P, Hu C, Hwang SB, Shue YK, Sucheck SJ. Liang CH, et al. Among authors: shue yk. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2123-8. doi: 10.1016/j.bmcl.2005.02.029. Bioorg Med Chem Lett. 2005. PMID: 15808482

6

Combinatorial synthesis of aminoglycoside libraries.

Sucheck SJ, Shue YK. Sucheck SJ, et al. Among authors: shue yk. Curr Opin Drug Discov Devel. 2001 Jul;4(4):462-70. Curr Opin Drug Discov Devel. 2001. PMID: 11727311 Review.

7

Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2.

Carcanague D, Shue YK, Wuonola MA, Uria-Nickelsen M, Joubran C, Abedi JK, Jones J, Kühler TC. Carcanague D, et al. Among authors: shue yk. J Med Chem. 2002 Sep 12;45(19):4300-9. doi: 10.1021/jm020868v. J Med Chem. 2002. PMID: 12213071

8

Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus.

Elliott RL, Kopecka H, Bennett MJ, Shue YK, Craig R, Lin CW, Bianchi BR, Miller TR, Witte DG, Stashko MA, et al. Elliott RL, et al. Among authors: shue yk. J Med Chem. 1994 Jan 21;37(2):309-13. doi: 10.1021/jm00028a015. J Med Chem. 1994. PMID: 8295219

9

Novel Asp32-replacement tetrapeptide analogues as potent and selective CCK-A agonists.

Elliott RL, Kopecka H, Tufano MD, Shue YK, Gauri AJ, Lin CW, Bianchi BR, Miller TR, Witte DG, Stashko MA, et al. Elliott RL, et al. Among authors: shue yk. J Med Chem. 1994 May 27;37(11):1562-8. doi: 10.1021/jm00037a005. J Med Chem. 1994. PMID: 8201590

10

Double bond isosteres of the peptide bond: synthesis and biological activity of cholecystokinin (CCK) C-terminal hexapeptide analogs.

Shue YK, Tufano MD, Carrera GM Jr, Kopecka H, Kuyper SL, Holladay MW, Lin CW, Witte DG, Miller TR, Stashko M, et al. Shue YK, et al. Bioorg Med Chem. 1993 Sep;1(3):161-71. doi: 10.1016/s0968-0896(00)82117-3. Bioorg Med Chem. 1993. PMID: 8081848

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page